Direxion Daily TSLA Bull 2X Shares (NASDAQ: TSLL)

Ultime notizie per Direxion Daily TSLA Bull 2X Shares (NASDAQ:TSLL)

Direxion Daily TSLA Bull 2X Shares

Consumer Cyclical

Direxion

The fund, under normal circumstances, invests at least 80% of its net assets (plus any borrowings for investment purposes) in the securities of TSLA and financial instruments, such as swap agreements and options, that provide leveraged exposure to TSLA. The fund is non-diversified.

Gs Financial Square Treasury Instruments Fund

Dreyfus Govt Cash Man Ins

Dreyfus Trsy Prime Cash Mgmt - In 0 -

Tesla, Inc.

Goldman Sachs Fin Gov 465 Institut

Direxion Daily TSLA Bull 1.5X Shares

TASSAL GROUP LTD ORD by Tassal Group, Ltd.

In the last three months, 8 analysts have published ratings on Traeger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COOK#NYSE">COOK</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $2.94, a high estimate of $5.00, and a low estimate of $2.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 22.83%. 
<img src="https://www.benzinga.com/files/images/story/2025/1744027275_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Traeger by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;---------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Joseph Feldman &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Market Perform &#x7C; $2.50&#x7C;$2.50 &#x7C; 
&#x7C;Megan Alexander &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Underweight &#x7C; $2.50&#x7C;$3.00 &#x7C; 
&#x7C;Nik Modi &#x7C;RBC Capital &#x7C;Lowers &#x7C;Sector Perform &#x7C; $2.00&#x7C;$2.75 &#x7C; 
&#x7C;Peter Keith &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $2.50&#x7C;$3.75 &#x7C; 
&#x7C;Peter Benedict &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $2.50&#x7C;$3.50 &#x7C; 
&#x7C;Brian McNamara &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $5.00&#x7C;$7.00 &#x7C; 
&#x7C;Joseph Feldman &#x7C;Telsey Advisory Group&#x7C;Lowers &#x7C;Market Perform &#x7C; $2.50&#x7C;$4.00 &#x7C; 
&#x7C;Joseph Feldman &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Outperform &#x7C; $4.00&#x7C;$4.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Traeger. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Traeger compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Traeger's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Traeger's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/COOK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Traeger analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Traeger</h2>
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
<h3>Traeger's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Traeger showcased positive performance, achieving a revenue growth rate of 3.16% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Traeger's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -4.13%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -2.5%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Traeger's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.84%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Traeger's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.57, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

COOK

8 Analysts Have This To Say About Traeger

20 analysts have expressed a variety of opinions on DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">10</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">7</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $57.75, a high estimate of $65.00, and a low estimate of $50.00. This current average reflects an increase of 8.04% from the previous average price target of $53.45. 
<img src="https://www.benzinga.com/files/images/story/2025/1744027260_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of DraftKings among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;------------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Bernie McTernan &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $65.00&#x7C;$65.00 &#x7C; 
&#x7C;Jordan Bender &#x7C;Citizens Capital Markets&#x7C;Lowers &#x7C;Market Outperform&#x7C; $57.00&#x7C;$60.00 &#x7C; 
&#x7C;Jordan Bender &#x7C;Citizens Capital Markets&#x7C;Maintains &#x7C;Market Outperform&#x7C; $60.00&#x7C;$60.00 &#x7C; 
&#x7C;Mike Hickey &#x7C;Benchmark &#x7C;Raises &#x7C;Buy &#x7C; $51.00&#x7C;$44.00 &#x7C; 
&#x7C;Stephen Grambling &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $53.00&#x7C;$49.00 &#x7C; 
&#x7C;Joseph Greff &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $61.00&#x7C;$53.00 &#x7C; 
&#x7C;Jordan Bender &#x7C;JMP Securities &#x7C;Raises &#x7C;Market Outperform&#x7C; $60.00&#x7C;$50.00 &#x7C; 
&#x7C;Daniel Politzer &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $60.00&#x7C;$53.00 &#x7C; 
&#x7C;Matt Farrell &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $60.00&#x7C;$48.00 &#x7C; 
&#x7C;Brandt Montour &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $60.00&#x7C;$50.00 &#x7C; 
&#x7C;Barry Jonas &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $60.00&#x7C;$50.00 &#x7C; 
&#x7C;Jeffrey Stantial &#x7C;Stifel &#x7C;Raises &#x7C;Buy &#x7C; $57.00&#x7C;$48.00 &#x7C; 
&#x7C;Bernie McTernan &#x7C;Needham &#x7C;Raises &#x7C;Buy &#x7C; $65.00&#x7C;$60.00 &#x7C; 
&#x7C;Mike Hickey &#x7C;Benchmark &#x7C;Raises &#x7C;Buy &#x7C; $51.00&#x7C;$44.00 &#x7C; 
&#x7C;Jordan Bender &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $50.00&#x7C;$50.00 &#x7C; 
&#x7C;Michael Graham &#x7C;Canaccord Genuity &#x7C;Raises &#x7C;Buy &#x7C; $60.00&#x7C;$54.00 &#x7C; 
&#x7C;Bernie McTernan &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $60.00&#x7C;$60.00 &#x7C; 
&#x7C;Bernie McTernan &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $60.00&#x7C;$60.00 &#x7C; 
&#x7C;Lance Vitanza &#x7C;TD Cowen &#x7C;Lowers &#x7C;Buy &#x7C; $51.00&#x7C;$55.00 &#x7C; 
&#x7C;Joseph Stauff &#x7C;Susquehanna &#x7C;Lowers &#x7C;Positive &#x7C; $54.00&#x7C;$56.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to DraftKings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DraftKings compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of DraftKings's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of DraftKings's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DKNG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on DraftKings analyst ratings.</a>
<h2>All You Need to Know About DraftKings</h2>
DraftKings got its start in 2012 as an innovator in daily fantasy sports. Then, following a Supreme Court ruling in 2018 that allowed states to legalize online sports wagering, the company expanded into online sports and casino gambling, where it generally holds the number two or three revenue share position across states in which it competes. DraftKings is now live with online or retail sports betting in about 25 states and iGaming in five states, with both products available to around 40% of Canada's population. In 2024, sports revenue was 61% of total sales, i-gaming 32%, and fantasy and lottery 7%. The company also operates a non-fungible token commissioned-based marketplace and develops and licenses online gaming products.
<h3>Financial Milestones: DraftKings's Journey</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: DraftKings displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 13.15%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: DraftKings's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -9.68%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): DraftKings's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -12.92%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): DraftKings's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -3.15%, the company may face hurdles in achieving optimal financial returns.
Debt Management: DraftKings's debt-to-equity ratio is below the industry average at 1.32, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DKNG

20 Analysts Have This To Say About DraftKings

Back in 2016, long before ChatGPT became a household name, OpenAI founder Sam Altman was already thinking about what happens when <a href="https://www.benzinga.com/personal-finance/24/07/39998742/sam-altmans-dream-of-a-universal-basic-income-is-one-step-closer-with-the-help-of-open-ai">technology starts replacing jobs</a>. His question wasn't subtle: If people were handed free money, would they just sit around and play video games—or would they build something great?
So, he tested it.
In a <a href="https://www.ycombinator.com/blog/basic-income">blog post on Y Combinator's site</a>, Altman laid out the big idea: "Do people sit around and play video games, or do they create new things? Are people happy and fulfilled? Do people, without the fear of not being able to eat, accomplish far more and benefit society far more?"
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.</li>
</ul>
He argued that as AI makes work easier—or even unnecessary—universal basic income might become essential. And yes, he was serious enough to fund the research himself.
The result? One of the largest guaranteed income studies ever conducted in the U.S.
Launched in 2020 through OpenResearch, the <a href="https://www.openresearchlab.org/studies/unconditional-cash-study/study">Unconditional Cash Study</a> gave 3,000 participants in Texas and Illinois $1,000 a month for three years. No strings attached. A control group of 2,000 received $50 a month. All participants had incomes within 300% of the federal poverty line—many earning less than $29,000 a year. That extra $1,000 meant a roughly 40% income boost for most.
So, what did people do with the money? Not surprisingly, the essentials came first: food, rent, gas. The data showed no luxury splurges or gaming binges—just survival, with a bit more breathing room.
And what about work?
Trending: These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a>
According to lead researcher Eva Vivalt, an economics professor at the University of Toronto, recipients worked 1.3 to 1.4 hours less per week than the control group. Instead of hustling those extra hours, they used the time for, well, life. "People are doing more stuff," Vivalt told <a href="https://www.cbsnews.com/news/sam-altman-universal-basic-income-study-open-research/">CBS News in a 2024 interview</a>. "And if the results say people value having more leisure time—that this is what increases their well-being—that's positive."
Altman was onto something. As AI grows more capable, we're entering a world where <a href="https://www.benzinga.com/personal-finance/25/03/44481583/bill-gates-thinks-you-might-only-work-2-3-days-a-week-thanks-to-ai-but-also-says-legitimately-people-are-like-wow-this-is-a-bit-scary">some jobs will be automated</a>, others may vanish, and plenty of people could end up working fewer hours by default. Elon Musk, for one, has floated the idea that basic income might be the future, once <a href="https://www.benzinga.com/personal-finance/25/02/43994419/i-dont-think-were-going-to-have-a-choice-elon-musk-predicts-universal-income-will-eventually-be-high-but-fears-people-will-feel">AI makes 40-hour workweeks optional</a>.
But here's where it gets real: the study showed no measurable improvement in job quality or wages. The theory was that financial stability would let people wait for better jobs or leave bad ones. It didn't pan out that way—at least not yet.
See Also: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
Health care usage did go up, though—by a lot. Hospitalizations rose by 26%, and ER visits jumped 10%, showing that when people actually have money, they do something about lingering medical issues.
<a href="https://www.bloomberg.com/news/articles/2024-07-22/ubi-study-backed-by-openai-s-sam-altman-bolsters-support-for-basic-income">Bloomberg</a> also reported that as the years went on, participants didn't just spend smarter—they started thinking bigger. They became more future-focused, building budgets, saving more, and making plans for things like college or starting a business.&nbsp;
Some even moved to new neighborhoods—more than four percentage points higher than the control group. A few chased better school districts; others finally ditched the couch-surfing life and got places of their own.
Bottom line? Sam Altman didn't just wonder what would happen if people had guaranteed income—he found out. And while no one sat around playing games all day, what they did do says a lot about what happens when you give people time, space, and choice.
Read Next:
<ul>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

Personal Finance

Sam Altman Asked What People Would Do With Free Money, 'Sit Around and Play Video Games or Create Something?' — He Gave Away $1,000 a Month to Find Out

Jefferies analyst Julien Dumoulin-Smith upgrades ONE Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGS#NYSE">OGS</a>) from Hold to Buy and raises the price target from $76 to $84.

News

Upgrades

Price Target

Jefferies Upgrades ONE Gas to Buy, Raises Price Target to $84

Jefferies analyst Jonathan Matuszewski upgrades Scotts Miracle Gro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) from Hold to Buy and lowers the price target from $72 to $69.

Jefferies Upgrades Scotts Miracle Gro to Buy, Lowers Price Target to $69

Jefferies analyst Andrew Tsai initiates coverage on Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy rating and announces Price Target of $200.

Initiation

AXSM

Jefferies Initiates Coverage On Axsome Therapeutics with Buy Rating, Announces Price Target of $200

<a href="https://www.icumed.com/">ICU Medical Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>), a worldwide leader in the development, manufacture and sale of innovative medical devices, has announced 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA) for the Plum Solo&#x2122; precision IV pump, a single-channel complement to the dual-channel Plum Duo&#x2122;. ICU Medical also received 510(k) clearance for updated versions of the Plum Duo precision IV pump and LifeShield&#x2122; infusion safety software, completing the initial launch of the <a href="https://www.icumed.com/landing-pages/iv-performance-platform/">ICU Medical IV Performance Platform</a>. With these FDA clearances, ICU Medical is introducing its <a href="https://www.icumed.com/about-us/clinical-connections/introducing-precision-infusion-pumps/">new category of precision IV pumps</a> and expanding the ICU Medical IV Performance Platform.
Unlike traditional pumps that rely on specific setups and conditions for accurate delivery, precision IV pumps are designed to address delivery variability while supporting the increasing need for accurate data in modern patient care. Built on the unique cassette technology in the <a href="https://www.icumed.com/products/infusion-therapy/infusion-pumps-and-software/plum-large-volume-pumps/plum-360-large-volume-infusion-pump/">Best in KLAS award-winning Plum 360&#x2122;</a>, the <a href="https://www.icumed.com/products/infusion-therapy/infusion-pumps-and-software/plum-large-volume-pumps/plum-precision-iv-pumps/">Plum Solo and Plum Duo precision IV pumps</a> deliver ±3% accuracy in real-world conditions and eliminate the infusion inconsistencies found in traditional pumps, providing clinicians with predictable performance and reliable infusion documentation.

Government

Regulations

ICUI

ICU Medical Gets FDA Green Light for New Precision IV Pumps, Launches Solo and Duo Models

Compass Point analyst Dominick Gabriele downgrades Q2 Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QTWO#NYSE">QTWO</a>) from Buy to Neutral.

Downgrades

QTWO

Compass Point Downgrades Q2 Holdings to Neutral

Compass Point analyst Giuliano Bologna upgrades Ally Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>) from Neutral to Buy and raises the price target from $37 to $41.

ALLY

Compass Point Upgrades Ally Financial to Buy, Raises Price Target to $41

Canaccord Genuity analyst David Hynes maintains DigitalOcean Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCN#NYSE">DOCN</a>) with a Buy and lowers the price target from $50 to $45.

DOCN

Canaccord Genuity Maintains Buy on DigitalOcean Holdings, Lowers Price Target to $45

The shares of Strategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) plunged 9.24% during the Monday pre-market trading session as Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) tumbled 7% amid President Donald Trump&#8216;s tariff woes.
What Happened: Strategy, one of the largest corporate holders of the cryptocurrency, felt the brunt after Bitcoin hit a low of $77,097.74<a href="https://www.benzinga.com/trading-ideas/movers/25/04/44659799/bitcoin-plunges-below-80000-ethereum-dogecoin-crash-as-cryptocurrencies-mirror-stocks-amid-trump-tariff-mayhem-analyst-flags-critical-support-level-for-btc"> before slightly</a> recovering to $78,000 on Sunday. Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) experienced a more severe fall, dipping below $1,600 for the first time since October 2023.
The trading volume for Bitcoin and Ethereum surged by 179% and 272%, respectively, indicating a high selling pressure. This drop followed a period of relative stability in cryptocurrency prices amidst intense stock market volatility on Friday.
Although Bitcoin initially demonstrated resilience, it is now mirroring the growing unease in the broader market. According to data from&nbsp;CoinGlass, in the past 24 hours, the crypto market experienced $570 million in liquidations, with long positions making up $493 million of the total. Bitcoin alone was responsible for more than $121 million of these liquidations.
As Bitcoin fell below the $80,000 threshold, prominent economist and Bitcoin skeptic Peter Schiff questioned Strategy co-founder Michael Saylor on whether he could stop the cryptocurrency from dropping further below his average purchase price of $68,000 by borrowing more funds to make large-scale purchases. 
At present, Strategy owns 528,185 BTC on its balance sheet
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="600" height="188" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07072024/image-60.png" alt="" class="wp-image-859692" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07072024/image-60.png 600w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07072024/image-60-300x94.png 300w" sizes="(max-width: 600px) 100vw, 600px" /></figure>
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/25/04/44658863/peter-lynchs-advice-if-you-cant-explain-to-an-11-year-old-in-two-minutes-or-less-why-you-own-the-stock-yo" target="_blank" rel="noreferrer noopener">Peter Lynch&#8217;s Advice: &#8216;If You Can&#8217;t Explain to an 11-Year-Old in Two Minutes or Less Why You Own the Stock, You Shouldn&#8217;t Own It&#8217;</a>
Why It Matters:  Earlier this month, investment banking firm Monness, Crespi, Hardt &amp; Co. predicted that Strategy&#8217;s aggressive bitcoin purchases may soon face a roadblock as funding options become limited. The firm also downgraded MSTR stock to &#8216;Sell&#8217; after initiating coverage at &#8216;Neutral&#8217; two weeks ago.
This recent crash in the cryptocurrency market comes in the wake of warnings from renowned cryptocurrency analyst Michaël van de Poppe. The analyst predicted that Bitcoin <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44661331/bitcoin-could-test-70k-amid-fears-of-black-monday-panic-says-analyst-van-de-poppe-as-global-markets-slide-on-trump-tariff-shock">could test</a> the $70,000 level amid panic selling, which he referred to as "Black Monday". This prediction seems to be coming true as the cryptocurrency market experiences its worst selloff since March 2020.
Meanwhile, analyst Ali Martinez has anticipated a significant price movement for Bitcoin, while economic analyst Jesse Colombo identified $77,500 as&nbsp;a &#8220;critical support level&#8221; for&nbsp;the cryptocurrency, warning of a sharp plunge if this level fails.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/25/04/44644765/tom-lee-predicts-a-market-rebound-after-april-9-as-absurd-tariffs-could-spur-potential-negotiations" target="_blank" rel="noreferrer noopener">Tom Lee Predicts a Market Rebound After April 9 As &#8216;Absurd&#8217; Tariffs Could Spur Potential Negotiations &#8211; Grayscale Bitcoin Mini Trust (BTC) Common units of fractional undivided beneficial interest (ARC</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Markets

Tech

$BTC

$ETH

MSTR

MSTR Stock Falls Over 9% In Monday Pre-Market: What's Going On?

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Neutral and maintains $75 price target.

Reiteration

SRPT

HC Wainwright & Co. Reiterates Neutral on Sarepta Therapeutics, Maintains $75 Price Target

Bally's Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALY#NYSE">BALY</a>) ("Bally's" or the "Company") today announced that it has entered into a binding term sheet with The Star Entertainment Group Limited (ASX: SGR) ("The Star") comprising a multi-tranche issuance of subordinated convertible notes and subordinated debt (together the "Notes") with an aggregate principal value of AUD $300 million (approximately USD $187 million1) (the "Transaction").
<a href="https://mma.prnewswire.com/media/2658995/SGR___Term_Sheet_with_Bally_s_Corporation__fully_executed_without_signature_pages.pdf?p=original"><img src="https://mma.prnewswire.com/media/2658995/SGR___Term_Sheet_with_Bally_s_Corporation__fully_executed_without_signature_pages.pdf?p=pdfthumbnail" alt="Bally's Corporation enters into a binding agreement with The Star for AUD 300 Million Strategic Capital Investment via Convertible Notes and Subordinated Debt" /></a>
The Star is an ASX-listed, leading Australian entertainment and gaming company, operating casino and resort properties in Sydney, Brisbane and the Gold Coast. The Star employs approximately 8,000 team members while also supporting downstream employment and other opportunities in the communities in which it operates.
Bally's will invest in and partner with The Star and bring a proven track record of revitalising underperforming casino businesses.&nbsp; Bally's will continue to work collaboratively with regulators and stakeholders to support a successful turnaround of The Star. Strategically, the Transaction is intended to preserve The Star's long-term potential, with Bally's committed to leveraging its operational expertise to deliver a more resilient and sustainable business for all stakeholders.
Soo Kim, Chairman of Bally's, said "This transaction provides Bally's the opportunity to infuse The Star with what it needs to regain its position as Australia's preeminent gaming destination.&nbsp; And it allows The Star shareholders to share in what we confidently believe will be a brighter future together."
George Papanier, President of Bally's adds, "We are excited to bring our reputation and operating expertise to a wonderful set of properties that operate in fantastic markets.&nbsp; We are up for the challenge."
Upon conversion of the Notes, Bally's would own up to ~56.7% of the fully diluted share capital of The Star assuming it subscribes for 100% of the Notes, noting that The Star's major shareholder, Investment Holdings Pty Ltd (which is controlled by the Mathieson family), may separately subscribe for a portion of the Notes, which would reduce Bally's' commitment by an equal amount.
The issue and conversion of certain tranches of Notes is subject to shareholder and regulatory approvals. The Star expects to hold a shareholder meeting in the coming months. In the interim a Bally's representative will join The Star board as an observer. Upon conversion of the Notes, additional and/or replacement directors will be appointed to ensure majority Board representation, subject to regulatory approvals.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Transaction Details
Under the binding term sheet executed on 6 April 2025, Bally's will invest AUD 300,000,000 (approximately USD $187 million1) through a combination of subordinated convertible notes and subordinated debt, in two tranches (refer below).
The Notes are convertible into shares such that Bally's will own approximately 56.7% of The Star's fully diluted share capital post-conversion,
<ul>
<li>Tranche 1 Notes:
<ul>
<li>Tranche 1A: Convertible into shares representing 9.71% of The Star's pre-issue capital</li>
</ul>
</li>
<li>AUD $22.3m (approximately USD $13.9m1)
<ul>
<li>Tranche 1B: Convertible into shares representing 4.85% of The Star's pre-issue capital</li>
</ul>
</li>
<li>AUD $11.1m (approximately USD $6.9m1)
<ul>
<li>Tranche 1C Subordinated Debt: Subordinated non-convertible debt</li>
</ul>
</li>
<li>Subordinated Debt of&nbsp;AUD $66.6m (approximately USD $41.5m1).&nbsp; This amount may be increased in certain circumstances, including if regulatory approvals related to the issuance and conversion of the Tranche 2&nbsp; Notes are not obtained within specified periods.</li>
<li>Tranche 2 Notes: Convertible into shares representing 50.3% of The Star's pre-issue capital
<ul>
<li>AUD $266.6m (approximately USD $166.2m1) with the principal amount of the Trance 1C Subordinated Debt being applied to reduce the amount payable by Bally's on the issue of the Tranche 2 Notes.</li>
</ul>
</li>
<li>The conversion price is fixed at&nbsp;AUD 0.08 per share, with customary anti-dilution protections.</li>
<li>The Notes mature on 2 July 2029, with automatic redemption of principal, accrued interest, and any outstanding payment-in-kind ("PIK") liability if not converted.</li>
<li>Interest rate of 9.0% per annum, payable quarterly.</li>
</ul>
Funding Details and Approvals
Bally's has available funds to support the Transaction. The issuance and conversion of certain tranches of Notes is subject to receipt of shareholder approval, regulatory approvals, execution of long-form transaction documents and certain consents.
The binding term sheet is attached to this release.

BALY

Bally's to Invest $187M in Australia's The Star, Eyes 57% Stake Through Convertible Notes Deal

Under the terms of the agreement, ABL Bio will receive up to £77.1 million in upfront and near-term payments, including an immediate upfront payment of £38.5 million, research milestones and potential program expansion. In total, ABL Bio is eligible to receive up to £2.075 billion in research, development, regulatory and commercialization milestone payments&nbsp;across multiple potential programs. ABL Bio will receive tiered royalties on net sales if products are successfully commercialized. As part of the agreement, ABL Bio will transfer Grabody-B-related technology and know-how to GSK, while GSK will assume responsibility for preclinical and clinical development, manufacturing, and commercialization.

Biotech

Large Cap

Health Care

Contracts

General

ABL Bio Announced A Worldwide Licensing Agreement With GSK To Develop Medicines For Neurodegenerative Diseases By Utilizing ABL Bio's Blood-brain Barrier Shuttle Platform, Grabody-B, ABL Bio Will Receive Up To £2.075B Including £77.1M In Upfront And Near-term Payments

WIIM

BABA

BEKE

BILI

DADA

New Oriental Education & Technology Group

GSX Techedu Inc. American Depositary Shares

GOTU

HTHT

Citigourp Global Markets 2% Protected Notes Linked To The Djia

UXIN

XPEV

YUMC

Shares of US-listed Chinese companies are trading lower after President Trump last week imposed 34% tariffs on China. In Retaliation, China imposed a 34% tariff on US goods.

QQQ: -5% &#x7C; <a href="https://www.benzinga.com//node/44663638">Major indexes are lower on continued weakness following President Trump's recent tariff announcements, which have caused global trade war concerns.</a>
&nbsp;
&nbsp;

Movers

Trading Ideas

Market-Moving News for April 7th

STLA

TSLA

Shares of auto-related stocks are trading lower as global markets continue to decline following President Trump's announcement of sweeping tariffs, which could raise auto prices and affect consumer demand. Additionally, auto part tariffs could raise prices for producers.

Chardan Capital analyst Keay Nakae maintains Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) with a Buy and maintains $20 price target.

SONN

Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Maintains $20 Price Target

Benchmark analyst Cody Acree reiterates Tower Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSEM#NASDAQ">TSEM</a>) with a Buy and maintains $60 price target.

TSEM

Benchmark Reiterates Buy on Tower Semiconductor, Maintains $60 Price Target

MasterCraft Boat Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCFT#NASDAQ">MCFT</a>) (the "Company"), today announced that Tim Oxley, Chief Financial Officer, has decided to retire from the Company, effective December 31, 2025. Scott Kent, Vice President of Finance, will succeed Mr. Oxley as Chief Financial Officer, effective July 1, 2025. Mr. Oxley will transition to serve as a special advisor to the executive team/Board from July 1, 2025 until December 31, 2025, to ensure a smooth transition of responsibilities.
Mr. Kent has 33 years of professional experience, including 28 years of direct marine industry experience and is the ideal successor for the CFO role. He has served as Vice President of Finance for MasterCraft since 2018, leading the finance function, including accounting, FP&amp;A, financial reporting, and treasury. Throughout his tenure, he has also helped lead operational and strategic advancements across the business. Prior to joining MasterCraft, Mr. Kent served as Chief Financial Officer at Brunswick Boat Group and Recreational Boat Group, as well as various positions of increasing responsibility at Brunswick, Sea Ray Boats, and Price Waterhouse. Mr. Kent has a bachelor's of science in Accounting from the Milligan College and has held license as a CPA.

Comments

Direxion Daily TSLA Bull 2X Shares

Notizie

Ultime notizie per Direxion Daily TSLA Bull 2X Shares (NASDAQ:TSLL)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO